Skip to main content

Table 1 The profiles of eligible studies

From: The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis

Publication year

Study

Country

Age of patient

Mean (range or standard derivation)

Cut-off value by PSQ

CpGs

Sample source

No. patientsa

Disease status

Treatment experience

Score in NOS

2015

Dae Cheol Kim

Korea

51.4 (26.4–87.2)

9 %

5 CpGs

FFPE

104

Newly diagnosed GMB

No all patients treated with TMZ

5

2015

Robert W. Rapkinsb

Australia

58.3 (25.0–85.0)

9 %

5 CpGs

FFPE

303

Newly diagnosed GMB

Surgery + radiotherapy + TMZ+ adjuvant TMZ

6

2015

Robert W. Rapkinsb

Australia

57.8 (22.3–84.3)

9 %

5 CpGs

FFPE

303

Newly diagnosed GMB

Surgery + radiotherapy + TMZ+ adjuvant TMZ

5

2014

Veronique Quillien

France

58 (21.0–73.0)

9 %

16 CpGs

FFPE

89

Newly diagnosed GMB

Stupp protocol

5

2014

Vincent Peter Collins

UK

53 (41–60)

10 %

16 CpGs

FFPE

275

Recurrent high-grade GMB

PCV OR two TMZ schedules

5

2014

Dong Shen

China

56 (35–71)

10 %

12 CpGs

FFPE

128

Recurrent high-grade GMB

Surgery + radiotherapy + TMZ+ adjuvant TMZ

5

2012

Guido Reifenberge

Germany

74.1 (70.0–86.6)

8 %

5 CpGs

Frozen sample

85

Newly diagnosed GMB

Treated with alkylating agents

5

2012

Veronique Quillien

France

57.5 (21.0–73.0)

8 %

5 CpGs

FFPE and frozen sample

99

Newly diagnosed GMB

Standard care treatment

5

2011

Miyuki Uno

Brazil

50.2 (14.6)

10 %

5 CpGs

Frozen sample

29

Newly diagnosed GMB

Adjuvant radiotherapy and/or chemotherapy (carmustine)

5

2011

Shani Mulholland

Sweden

NA

10 %

16 CpGs

Frozen sample

362

GMB

Surgery + adjuvant treatment (no TMZ)

5

2009

J Dunn

UK

55 (18–68)

10 %

12 CpGs

FFPE or frozen sample

108

Newly diagnosed GMB

Surgery + radiotherapy + TMZ+ adjuvant TMZ

5

  1. Abbreviations: FFPE formalin-fixed paraffin-embedded, PCV chemotherapy procotol: procarbazine, CCNU, and vincristine
  2. aThe number of patients whose methylation status of MGMT promoter was measured successfully by PSQ
  3. bThis publication included two independently studies, Australian cohort (AGOG) and American cohort (UCLA)